Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
-Epigallocatechin-3-gallate (green tea) has potential as a novel therapeutic agent for patients with… multiple myeloma via induction of apoptosis mediated by modification of the redox system. Green
Continue readingWhile trying to predict the risk of smoldering multiple myeloma (SMM) from becoming full multiple myeloma (MM) is a worthwhile endeavor, no method of predicting SMM to full MM is 100% accurate. The study
Continue reading“Our study confirms that WB MRI detects skeletal disease in a higher number of treatment-naïve (Multiple Myeloma) patients than PET/CT..” What are the best imaging methods for both myeloma
Continue reading“researchers have linked antioxidant supplements — including omega-3 fats, curcumin, selenium, resveratrol, and vitamin C — with various beneficial health outcomes.” Let me go on record
Continue readingChronic systemic inflammation becomes increasingly associated with risk of death, loss of cognitive function and increasing dependency Could the progression of pre-MM (SBP, MGUS, SMM) be slowed or even
Continue readingMultiple myeloma is defined as smoldering (asymptomatic) or active (symptomatic). The NCCN criteria for smoldering multiple myeloma are as follows The presence of any of the CRAB criteria or any of
Continue readingThe studies below document coffee’s heart and brain health promoting, anti-stroke, anti-diabetic, and all around ability to reduce risk of death. I’m a long-term multiple myeloma survivor
Continue readingSeveral prediction models for SMM progression to MM have been proposed and are typically based on a combination of biomarkers at diagnosis, such as level of MP, BMPCs, and FLCr. Hi David- I have been
Continue reading“…though they said their model was not able to accurately discriminate between patients with one or two risk factors during the first 2 to 3 years…” Let’s be clear. A risk
Continue reading“…there is a need to better understand the significant heterogeneity in SMM and to identify the patients who benefit the most from early treatment from those who can safely defer treatment.” I
Continue reading“The optimal endpoint for studies evaluating progression from SMM to active MM is OS or a substantial improvement in the quality of life.” For as long as I can remember, conventional oncology
Continue readingIf you are not young, early stage (MM) and low-risk then, according to the research below, your average first remission will be about 2-3 years and your OS will be about the average 5-7 years. Hi David-
Continue reading